Spero Therapeutics ( (SPRO) ) has shared an update.
Spero Therapeutics announced a significant workforce reduction to realign focus on tebipenem HBr and other R&D projects after the SPR720 trial for NTM-PD didn’t meet its primary endpoint. The restructuring aims to extend the company’s cash runway into mid-2026, supporting ongoing trials and strategic initiatives. The company remains committed to advancing its pipeline, including the PIVOT-PO Phase 3 trial for tebipenem HBr, amidst potential challenges and the need for further funding.
For a thorough assessment of SPRO stock, go to TipRanks’ Stock Analysis page.
